BCL2 and acute myeloid leukemia: While some studies have reported that drug sensitivities to BH3-mimetics are related to expression levels of specific BCL-2 family proteins, especially the protein targeted by the drug or other pro-survival relatives [35–37, 39–47], such correlations were either weak or absent in particular cancers, including CRC [62] and AML [63], and B-cell lymphoma [64].